ARTICLE
Volume 4,Issue 2
16 October 2025
Establishment and Real-World Application of an Adverse Reaction Monitoring System for Targeted Therapy of Antitumor Drugs
Xiaoyan Li ,
Jianfu Zhao ,
Genshen Ye ,
Yongjuan Ding ,
Xi Liu ,
Zhikun Liang ,
Qiang Chen
Show Less
1
Pharmacy Department, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, Guangdong, China,
2
Oncology Department, The First Affiliated Hospital of Jinan University, Guangzhou 510630, Guangdong, China,
3
Zhiyan Health Institute of Sciences, Shanghai 510630, China,
4
Pharmacy Department, Affiliated Hospital of Jiangnan University, Wuxi 214122, Jiangsu, China,
5
Pharmacy Department, Zhongshan Torch Development Zone People’s Hospital, Zhongshan 528400, Guangdong, China,
OTD 2025 , 3(3), 24–29;
https://doi.org/10.26689/otd.v3i3.12258
© 2025 by the Authors. Licensee: Bio-Byword Scientific Publishing Pty Ltd, Australia. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract
This multicenter prospective observational study aims to construct an adverse reaction monitoring system for molecular targeted antitumor drugs and explore its real-world application. By recruiting patients receiving molecular targeted therapy from outpatient, inpatient, and pharmacy settings, we collected comprehensive data including patient demographics, disease information, treatment regimens, and adverse reactions. The adverse reactions were graded according to CTCAE v5.0. With a planned enrollment of at least 100,000 patients over five years, this study will conduct descriptive analysis and build prediction models for adverse reactions. The results will contribute to establishing a national monitoring network and database, updating clinical guidelines, and enhancing the safety of molecular targeted therapy.
References
Sehn LH, Chua N, Mayer J, et al., 2016, Obinutuzumab Plus Bendamustine Versus Bendamustine Monotherapy in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (GADOLIN): A Randomised, Controlled, Open-Label, Multicentre, Phase 3 Trial. Lancet Oncol, 17(8): 1081–1093.
Mak JWY, Law AWH, Law KWT, et al., 2023, Prevention and Management of Hepatitis B Virus Reactivation in Patients With Hematological Malignancies in the Targeted Therapy Era. World J Gastroenterol, 29(33): 4942–4961.
Shi Q, Yang X, Ren L, et al., 2020, Recent Advances in Understanding the Hepatotoxicity Associated With Protein Kinase Inhibitors. Expert Opin Drug Metab Toxicol, 16(3): 217–226.
Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, et al., 2006, Pooled Safety Analysis of BAY 43-9006 (Sorafenib) Monotherapy in Patients With Advanced Solid Tumours: Is Rash Associated With Treatment Outcome? Eur J Cancer, 42(4): 548–556.
Funakoshi T, Latif A, Galsky MD, 2013, Risk of Hematologic Toxicities in Cancer Patients Treated With Sunitinib: A Systematic Review and Meta-Analysis. Cancer Treat Rev, 39(7): 818–830.
Zaja F, Tomadini V, Zaccaria A, et al., 2006, CHOP-Rituximab With Pegylated Liposomal Doxorubicin for the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma. Leuk Lymphoma, 47(10): 2174–2180.
Tanaka H, Takahashi K, Yamaguchi K, et al., 2018, Hypertension and Proteinuria as Predictive Factors of Effects of Bevacizumab on Advanced Breast Cancer in Japan. Biol Pharm Bull, 41(4): 644–648.
Galvano A, Guarini A, Iacono F, et al., 2019, An Update on the Conquests and Perspectives of Cardio-Oncology in the Field of Tumor Angiogenesis-Targeting TKI-Based Therapy. Expert Opin Drug Saf, 18(6): 485–496.
Je Y, Schutz FA, Choueiri TK, 2009, Risk of Bleeding With Vascular Endothelial Growth Factor Receptor Tyrosine-Kinase Inhibitors Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials. Lancet Oncol, 10(10): 967–974.
Choueiri TK, Schutz FA, Je Y, et al., 2010, Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials. J Clin Oncol, 28(13): 2280–2285.
Khorana AA, Francis CW, Culakova E, et al., 2007, Thromboembolism Is a Leading Cause of Death in Cancer Patients Receiving Outpatient Chemotherapy. J Thromb Haemost, 5(3): 632–634.
Piper-Vallillo AJ, Sequist LV, 2019, Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib. JACC CardioOncol, 1(2): 179–181.
Schiefer M, Hendriks LEL, Dinh T, et al., 2018, Current Perspective: Osimertinib-Induced QT Prolongation: New Drugs With New Side-Effects Need Careful Patient Monitoring. Eur J Cancer, 91: 92–98.
Lv B, Chen J, Liu XL, 2022, Anlotinib-Induced Hypertension: Current Concepts and Future Prospects. Curr Pharm Des, 28(3): 216–224.
Leslie I, Boos LA, Larkin J, et al., 2020, Avelumab and Axitinib in the Treatment of Renal Cell Carcinoma: Safety and Efficacy. Expert Rev Anticancer Ther, 20(5): 343–354.
Dikopf A, Wood K, Salgia R, 2015, A Safety Assessment of Crizotinib in the Treatment of ALK-Positive NSCLC Patients. Expert Opin Drug Saf, 14(3): 485–493.
Tamura Y, Tamura Y, 2022, Dasatinib-Induced Pulmonary Hypertension. Intern Med, 61(15): 2245–2246.
Share
Back to top
Bio-Byword Scientific Publishing Pty. Ltd.
We are committed to supporting the scientific community by publishing impactful research and fostering effective communication among scientists. We continuously seek ways to accelerate scientific progress while upholding transparency and open dialogue. Our goal is to make knowledge freely and barrier‑free accessible to all.
Contact us: info@bbwpublisher.com
Level 10, 50 Clarence Street Sydney, NSW 2000 Australia